DE69229269T2 - Peptidfragmente des menschlichen cytochrome p450 iid6, antikörper dagegen und ihre verwendungen in diagnostik - Google Patents
Peptidfragmente des menschlichen cytochrome p450 iid6, antikörper dagegen und ihre verwendungen in diagnostikInfo
- Publication number
- DE69229269T2 DE69229269T2 DE69229269T DE69229269T DE69229269T2 DE 69229269 T2 DE69229269 T2 DE 69229269T2 DE 69229269 T DE69229269 T DE 69229269T DE 69229269 T DE69229269 T DE 69229269T DE 69229269 T2 DE69229269 T2 DE 69229269T2
- Authority
- DE
- Germany
- Prior art keywords
- amino acids
- pro
- asp
- arg
- gln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 title claims description 26
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title claims 7
- 239000012634 fragment Substances 0.000 title abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 150000001413 amino acids Chemical class 0.000 claims abstract description 46
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims abstract description 20
- 238000003745 diagnosis Methods 0.000 claims abstract description 8
- 102000018832 Cytochromes Human genes 0.000 claims abstract 4
- 108010052832 Cytochromes Proteins 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 238000012544 monitoring process Methods 0.000 claims description 6
- 239000013060 biological fluid Substances 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- KHTIUAKJRUIEMA-HOUAVDHOSA-N Thr-Trp-Asp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O)=CNC2=C1 KHTIUAKJRUIEMA-HOUAVDHOSA-N 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 abstract description 6
- 102000007079 Peptide Fragments Human genes 0.000 abstract description 6
- 108010033276 Peptide Fragments Proteins 0.000 abstract description 6
- 208000006454 hepatitis Diseases 0.000 abstract description 5
- 231100000283 hepatitis Toxicity 0.000 abstract description 5
- 238000003748 differential diagnosis Methods 0.000 abstract description 4
- 208000002672 hepatitis B Diseases 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 4
- 230000002788 anti-peptide Effects 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 28
- 102000003849 Cytochrome P450 Human genes 0.000 description 19
- 238000010276 construction Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002529 anti-mitochondrial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- -1 9-fluorenylmethoxycarbonyl Chemical group 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 101710101549 Cytochrome P450 2D6 Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101000909129 Rattus norvegicus Cytochrome P450 2D26 Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9107363A FR2677653A1 (fr) | 1991-06-17 | 1991-06-17 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune. |
| PCT/FR1992/000539 WO1992022656A1 (fr) | 1991-06-17 | 1992-06-16 | Fragments peptidiques issus du cytochrome humain p450 iid6, anticorps anti-fragments peptidiques et leurs applications dans le diagnostic de l'hepatite auto-immune |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69229269D1 DE69229269D1 (de) | 1999-07-01 |
| DE69229269T2 true DE69229269T2 (de) | 1999-11-11 |
Family
ID=9413909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69229269T Expired - Fee Related DE69229269T2 (de) | 1991-06-17 | 1992-06-16 | Peptidfragmente des menschlichen cytochrome p450 iid6, antikörper dagegen und ihre verwendungen in diagnostik |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5830667A (enExample) |
| EP (1) | EP0589993B1 (enExample) |
| JP (1) | JP3284240B2 (enExample) |
| AT (1) | ATE180512T1 (enExample) |
| CA (1) | CA2111672A1 (enExample) |
| DE (1) | DE69229269T2 (enExample) |
| ES (1) | ES2133320T3 (enExample) |
| FR (1) | FR2677653A1 (enExample) |
| WO (1) | WO1992022656A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985542A (en) * | 1996-05-20 | 1999-11-16 | Sumitomo Chemical Company, Limited | Diagnostic kit |
| DE19805815C1 (de) * | 1998-02-13 | 1999-11-11 | Ansgar W Lohse | Diagnostikum zum Erkennen der autoimmunen Hepatitis |
| DE19930933B4 (de) * | 1998-07-10 | 2005-05-25 | Imtec Immundiagnostika Gmbh | Verfahren zur Bestimmung von anti-LKM 1-Antikörpern |
| US6787303B1 (en) | 1999-04-01 | 2004-09-07 | Alton Ochsner Medical Foundation | Identification of a novel retrovirus associated with primary sclerosing cholangitis and autoimmune hepatitis |
| CA2421680A1 (en) * | 2000-09-29 | 2002-04-04 | Merck & Co., Inc. | Antibodies for human cytochrome p450 2d6 |
| US20040096874A1 (en) * | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
| EP2454276A4 (en) * | 2008-07-17 | 2013-07-10 | Inter K Pty Ltd | THERAPEUTIC AGENTS |
| CN102955030A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体ana的试剂盒及其检测方法 |
| CN102707055A (zh) * | 2012-06-11 | 2012-10-03 | 郑州安图绿科生物工程有限公司 | 一种联合或单独检测自身免疫性肝病相关抗体的试剂盒及其检测方法 |
| CN102955027A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体抗lc-1抗体的试剂盒及其检测方法 |
| CN102955026A (zh) * | 2012-06-11 | 2013-03-06 | 郑州安图绿科生物工程有限公司 | 检测自身免疫性肝病相关抗体asma的试剂盒及其检测方法 |
| CR20230131A (es) | 2015-05-06 | 2023-06-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497) |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| EP3477303A1 (en) | 2017-10-27 | 2019-05-01 | Medizinische Hochschule Hannover | Method and means for diagnosing autoimmune hepatitis using autoantibody markers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106726A (en) * | 1990-02-16 | 1992-04-21 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV |
-
1991
- 1991-06-17 FR FR9107363A patent/FR2677653A1/fr active Granted
-
1992
- 1992-06-16 EP EP92912543A patent/EP0589993B1/fr not_active Expired - Lifetime
- 1992-06-16 WO PCT/FR1992/000539 patent/WO1992022656A1/fr not_active Ceased
- 1992-06-16 DE DE69229269T patent/DE69229269T2/de not_active Expired - Fee Related
- 1992-06-16 ES ES92912543T patent/ES2133320T3/es not_active Expired - Lifetime
- 1992-06-16 US US08/162,149 patent/US5830667A/en not_active Expired - Lifetime
- 1992-06-16 CA CA002111672A patent/CA2111672A1/en not_active Abandoned
- 1992-06-16 JP JP50076893A patent/JP3284240B2/ja not_active Expired - Fee Related
- 1992-06-16 AT AT92912543T patent/ATE180512T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP3284240B2 (ja) | 2002-05-20 |
| EP0589993A1 (fr) | 1994-04-06 |
| JPH06510663A (ja) | 1994-12-01 |
| US5830667A (en) | 1998-11-03 |
| ATE180512T1 (de) | 1999-06-15 |
| ES2133320T3 (es) | 1999-09-16 |
| CA2111672A1 (en) | 1992-12-23 |
| FR2677653A1 (fr) | 1992-12-18 |
| FR2677653B1 (enExample) | 1995-04-14 |
| EP0589993B1 (fr) | 1999-05-26 |
| WO1992022656A1 (fr) | 1992-12-23 |
| DE69229269D1 (de) | 1999-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69628336T2 (de) | Behandlung und diagnose helicobacter pylori infektionen | |
| DE69229269T2 (de) | Peptidfragmente des menschlichen cytochrome p450 iid6, antikörper dagegen und ihre verwendungen in diagnostik | |
| Franklin et al. | Structural units of human 7S gamma globulin | |
| DE69420556T2 (de) | Assay für troponin i aus dem herzmuskel | |
| DE3750339T2 (de) | HTLV-III umhüllende Peptiden. | |
| DE68918497T2 (de) | Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika. | |
| DE68916421T2 (de) | Synthetische peptidantigene zum nachweis von htlv-1-infektionen. | |
| DE3781078T2 (de) | Verwendunng eines peptids zur herstellung von zusammensetzungen fuer die linderung, behandlung und diagnose von autoimmunkrankheiten, insbesondere arthritis, zu diesem peptid analoge verbindungen, mikro-organismen, die dieses peptid oder eine zu diesem peptid analoge verbindung produzieren, als auch pharmazeutische und diagnostische zusammensetzungen und test kits. | |
| DE68925935T2 (de) | Antikörper gegen Interleukin-1-beta | |
| DE69737870T2 (de) | Medikamente für die diagnostik von autoimmunerkrankungen | |
| Langeland | A Clinical and Immunological Study of Allergy to Hen's Egg White: II, Antigens in Hen's Egg White Studied by Crossed Immunoelectrophoresis (CIE) | |
| DE69327529T2 (de) | Immunologisch mit HLA homologe HIV Protein Epitope | |
| DE69619405T2 (de) | Verbindungen und verfahren zum nachweis und zur vorbeugung von t.cruzi infektionen | |
| DE3218312A1 (de) | Monoklonale antikoerper, hybridoma-zellklone, verfahren zu ihrer herstellung und ihre verwendung zur erkennung von brustkrebs und maligner lymphogranulomatose | |
| US5047509A (en) | Abnormally glycosylated variants of a2 macroglobulin | |
| US5616685A (en) | snRNP-A antigen and fragments thereof | |
| DE68927635T2 (de) | Igm-antikörper gegen protamin | |
| DE69224134T2 (de) | Monoklonale Antikörper gegen Hepatitis-C-Virus | |
| DE68921360T2 (de) | Monoklonale Antikörper von Mäusen gegen das gp41 Protein von menschlichem Immunmangelsyndrom-Virus. | |
| DE69327239T2 (de) | Methoden and reagentien zur diagnose von autoantikörpern | |
| DE69733957T2 (de) | Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta | |
| Abrass | Evaluation of sequential glomerular eluates from rats with Heymann nephritis. | |
| DE3855280T2 (de) | Von mca 16-88 erkanntes antigen | |
| DE60014616T2 (de) | Antikörper gegen plazentaprotein 13 | |
| DE69433787T2 (de) | HTLV-I UND HTLV-II gp21 abgeleitete Peptide zur diagnostischen Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |